{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-000561","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.514903+00:00","generated_at":"2026-06-27T19:34:40.730657+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Foghorn Therapeutics appoints Steven Bellon as CSO; Carl Decicco to retire by Jan 31, 2022","bullets":["Carl Decicco steps down as CSO effective Jan 10, 2022; serves as Special Advisor through Jan 31, 2022 then retires.","Steven Bellon, PhD appointed as CSO effective Jan 10, 2022; joined Foghorn in 2016 as head of drug discovery.","Bellon brings 20+ years drug discovery experience from Amgen, Vertex, and Constellation Pharmaceuticals.","Decicco will receive base salary through Jan 31, 2022 and is eligible for FY2021 bonus; vested options exercisable until July 5, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-000561","json":"https://secwatch.observer/filing/0001628280-22-000561.json","markdown":"https://secwatch.observer/filing/0001628280-22-000561.md","text":"https://secwatch.observer/filing/0001628280-22-000561.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828022000561/0001628280-22-000561-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828022000561/fhtx-20220110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:34:40.730657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"368ac6b7c2","claim":"Steven Bellon was appointed as Chief Scientific Officer at Foghorn Therapeutics Inc..","evidence_excerpt":"On this same date, the Company announced that Steven Bellon, PhD. had been appointed to serve as the Company’s Chief Scientific Officer, effective as of January 10, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828022000561/0001628280-22-000561-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"d03cf32328","claim":"Carl Decicco departed as Chief Scientific Officer at Foghorn Therapeutics Inc..","evidence_excerpt":"Dr. Decicco will step down from his position as Chief Scientific Officer of the Company effective as of January 10, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828022000561/0001628280-22-000561-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}